Shanghai Fosun PharmaceuticalAnd FosunAccording to the joint announcement, Shanghai Fosun Pharmaceutical Industries agreed to purchase a total of 32.52 per cent of the target company from the selling shareholders at a consideration of about 1.108 billion yuan in cash, and plans to subscribe for a new registered capital of 47.96 million yuan with the 100 per cent equity stake of its subsidiary Yalifeng at a price of 2.898 billion yuan.

After the completion of the acquisition and capital increase, Shanghai Fosun Pharmaceutical Industry will hold about 73.01% of the total expanded equity of the target company, and the target company will become a subsidiary of Shanghai Fosun Pharmaceutical and Fosun. Shanghai Fosun Pharmaceutical Industry will hold 100% of Yalifeng through the target company.